RESUMEN
BACKGROUND: The WHO set the global immunisation threshold for COVID-19 at 70% to achieve worldwide protection against the disease. To date, global COVID-19 vaccine coverage is still below this threshold, in particular in several sub-Saharan African (SSA) countries, such as Madagascar. While factors influencing COVID-19 vaccine hesitancy have been widely explored in the past few years, research on drivers of COVID-19 vaccine uptake remains scarce. This study aimed at investigating drivers associated with COVID-19 vaccine uptake in the Boeny region of Madagascar. METHODS: The study used a cross-sectional survey design to collect data on drivers of vaccine uptake from a sample of adults recruited from 12 healthcare facilities between November 2022 and February 2023. Relative and absolute frequencies were used to summarize participants' characteristics. Prevalence ratios were estimated by Poisson regression to identify and compare sociodemographic and motivational drivers of vaccine uptake among those who were willing to get vaccinated against COVID-19 with those who had already been vaccinated. RESULTS: A total of 928 participants aged between 18 and 76 years were included in the study. Among those recruited, 44.9% (n = 417) had already been vaccinated and 55.1% (n = 511) were willing to receive their first dose of COVID-19 vaccine on the day of the interview. The proportions of those respondents who live in urban areas (56.5% vs. 43.8%) and who have high school or university education (46.6% vs. 35.8%) were higher for the uptake group, whereas the proportion of employed respondents (66.3% vs. 56.5%) was higher among those willing to get vaccinated. Vaccine being free of charge (aPR = 1.77 [CI 95%: 1.45-2.17]) and being able to travel again (aPR = 1.61 [CI 95%: 1.30-1.98]) were the drivers most strongly associated with higher vaccine uptake after adjustment for sociodemographic factors. CONCLUSIONS: This study shows that actual COVID-19 vaccine uptake is influenced by a different set of factors than willingness to get vaccinated. Taking this difference in drivers into account can inform more tailored vaccination strategies to increase worldwide coverage.
Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Población Rural , Humanos , Madagascar , Estudios Transversales , Adulto , Masculino , Femenino , Vacunas contra la COVID-19/administración & dosificación , Persona de Mediana Edad , COVID-19/prevención & control , Población Rural/estadística & datos numéricos , Adulto Joven , Adolescente , Anciano , Vacilación a la Vacunación/estadística & datos numéricos , Vacilación a la Vacunación/psicología , SARS-CoV-2RESUMEN
Aims: The prevalence of HIV in the general population of Madagascar is 0.3%. Some population groups, especially detainees are vulnerable to this infection. Our study was the first combined HIV survey of the detainees of Ankazondrano jail in Fianarantsoa. The study aims to determine the serological status of the detainees related to HIV infection and their risky behaviours for this infection.Methods: A descriptive cross-sectional survey of the detainees 18 years old and over was carried out in Ankazondrano jail in Fianarantsoa during September 2020.Results: The prevalence of HIV in the sample was zero; 89.43% of the detainees reported to have heard about HIV; only 15.45% had a general knowledge about it; 76.42% of them knew that a condom is a way of protection against HIV infection; however, they had wrong responses about protection against this infection. In fact, 47.97% of the surveyed detainees thought that HIV is transmitted by mosquito bites and 65.04% thought that it is transmitted by shaking hands. Almost one quarter of the detainees reported that there is no risk of HIV contraction in jail.Conclusion: In this study, nevertheless, the prevalence of HIV is zero; detainees of Ankazondrano jail are a vulnerable group to HIV due to their lack of knowledge of this infection and the fact that they undertook risky behaviours.
Asunto(s)
Infecciones por VIH , Prisioneros , Adolescente , Adulto , Estudios Transversales , Infecciones por VIH/epidemiología , Humanos , Cárceles Locales , Madagascar/epidemiologíaRESUMEN
The prevalence of infections and risk factors that go along with them give insights into the burden of disease and effectiveness of infection prevention and control strategies. In this study we investigated the burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated epidemiological factors in three regions of Madagascar among healthcare workers. Between May and June 2021, we conducted a multi-site cross-sectional study among healthcare workers in eight University Hospital Centers, during the local second wave and before the coronavirus disease 2019 vaccination campaign in three regional capitals of Madagascar. We collected demographic information and relevant SARS-CoV-2 exposure history and tested for both immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay and active SARS-CoV-2 infection using real-time reverse transcription-polymerase chain reaction. A total of 1006 healthcare workers enrolled in the study out of which 53.8% tested positive for either acute infection or SARS-CoV-2 antibodies. Approximately 50% of the participants reported receiving inadequate training on SARS-CoV-2 and associated infection prevention and control measures, inadequate supply of Personal Protective Equipment (PPE) and discomfort when using available PPE. Prevalence of acute infection was 3.4% without statistically significant variation in the different regions or health facilities as well as the different profession groups and units of work. Average seroprevalence of SARS-CoV-2 IgG antibodies was 52.0%, varying between 47.8% and 53.3% across the different regions. No significant difference was observed for region, gender, profession, and different risk groups. Predictive multivariable model showed significant association between seropositivity and healthcare facility and age (p<0.05). Our results revealed high infection rate of SARS-CoV-2 in HCWs in all three selected regions of Madagascar. The high disease burden identified in the study population might characterize the extent of high undocumented infection rates in HCWs in other regions of Madagascar.
Asunto(s)
Anticuerpos Antivirales , COVID-19 , Personal de Salud , SARS-CoV-2 , Humanos , Madagascar/epidemiología , COVID-19/epidemiología , Femenino , Masculino , Adulto , Estudios Transversales , Personal de Salud/estadística & datos numéricos , SARS-CoV-2/aislamiento & purificación , SARS-CoV-2/inmunología , Persona de Mediana Edad , Anticuerpos Antivirales/sangre , Inmunoglobulina G/sangre , Prevalencia , Adulto Joven , Factores de Riesgo , Estudios SeroepidemiológicosRESUMEN
Introduction: Non-communicable diseases (NCDs), the leading cause of death globally, are estimated to overtake communicable diseases in sub-Sahara Africa, where healthcare workers (HCWs) play a crucial role in prevention and treatment, but are in extreme shortage, thereby increasing the burden of NCDs among this specific population. To provide evidence for policy-making, we assessed the NCD burden, associated factors and treatment among HCWs in four sub-Saharan African countries. Materials and methods: We conducted a cross-sectional study across four sub-Saharan African countries [Côte d'Ivoire (CIV), Democratic Republic of the Congo (DRC), Madagascar (MDG), and Nigeria (NIG)] between February and December 2022. In a standardized questionnaire, sociodemographic, chronic disease and treatment data were self-reported. We estimated the prevalence of (1) at least one chronic disease, (2) hypertension, and used backward elimination logistic regression model to identify risk factors. Results: We recruited a total of 6,848 HCWs. The prevalence of at least one chronic disease ranged between 9.7% in NIG and 20.6% in MDG, the prevalence of hypertension between 5.4% in CIV and 11.3% in MDG. At most, reported treatment rates reached 36.5%. The odds of each of both outcomes increased with age (at least one chronic disease adjusted odds ratio: CIV: 1.04; DRC: 1.09; MDG: 1.06; NIG: 1.10; hypertension: CIV: 1.10; DRC: 1.31; MDG: 1.11; NIG: 1.11) and with BMI (at least one chronic disease: CIV: 1.10; DRC: 1.07; MDG: 1.06; NIG: 1.08; hypertension: CIV: 1.10; DRC: 1.66; MDG: 1.13; NIG: 1.07). Odds of both outcomes were lower among males, except in CIV. In NIG, the odds of both outcomes were higher among medical doctors and odds of hypertension were higher among those working in secondary care. In MDG, working in secondary care increased and working as auxiliary staff decreased the odds of at least one chronic disease. Conclusion: The prevalence of self-reported chronic disease varied across the four sub-Saharan countries with potentially very low treatment rates. We identified several individual (age, sex, and BMI) and occupational (profession, level of healthcare) factors that influence the odds of NCDs. These factors should be taken into account when developing interventions addressing the burden and management of NCDs among HCWs.
Asunto(s)
Personal de Salud , Enfermedades no Transmisibles , Humanos , Estudios Transversales , Masculino , Enfermedades no Transmisibles/epidemiología , Femenino , Adulto , Personal de Salud/estadística & datos numéricos , Persona de Mediana Edad , África del Sur del Sahara/epidemiología , Prevalencia , Factores de Riesgo , Hipertensión/epidemiología , Encuestas y Cuestionarios , Enfermedad Crónica/epidemiología , Costo de Enfermedad , Côte d'Ivoire/epidemiologíaRESUMEN
BACKGROUND: In the context of the Covid-19 pandemic and following the increasing number of suspicious Covid-19 cases in Madagascar, Malagasy laboratories are overflowed mainly due to lack of human resource and available material restriction. The development and validation of rapid and easy-to-perform diagnostic methods are worth of interest and high priority. The aim of this prospective study was to evaluate the performances of a rapid immunochromatographic test for the detection of SARS-CoV-2 antigen, in comparison to Reverse transcription polymerase chain reaction (RT-PCR). METHODS: The fluorescence immunochromatographic SARS-CoV-2 antigen test StandardTM Q COVID-19 Ag Test (SD Biosensor Republic Korea) was evaluated in samples derived from patients who were examined for disease categories. Diagnostic accuracy was determined in comparison to SARS-CoV-2 RT-PCR considered as gold standard. RESULTS: A total of 200 samples were included; 94 were RT-PCR positive. Median patients' age was 38.36 years, 63.5 % were male. Overall sensitivity and specificity of the Standard TM Q COVID-19 Ag (SD Biosensor® Republic Korea) were 62.66 % and 100 %, the sensitivity was significantly higher (100 %) in samples with high viral loads (Ct<29). CONCLUSIONS: This antigen-based immunofluorescence RDT could be the potential to become an important tool for the early diagnosis of SARS-CoV-2 particularly in situations with limited access to molecular methods particularly in rural area of Madagascar.
Asunto(s)
COVID-19 , SARS-CoV-2 , Adulto , Antígenos Virales , Humanos , Masculino , Pandemias , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: The incidence of the 2020 COVID-19 epidemic in Africa seems to be different from that of the rest of the world, however its true extent is probably underestimated. Conducting population based sero-surveys during the epidemic has moreover been extremely challenging, driving our group and others to study blood donor samples. METHODS: We collected regional epidemiological COVID-19 surveillance data, and simultaneously monitored anti-SARS-CoV-2 antibody seroprevalences monthly throughout the epidemic in 5 major Region-associated Blood Transfusion Centres of Madagascar over a period of 9 months. FINDINGS: Soon after attaining the first epidemic peaks between May and August 2020, both crude and population-weighted test-performance-adjusted seroprevalences of anti-SARS-CoV-2 antibodies was in Malagasy blood donors rapidly increased up to over 40% positivity. INTERPRETATION: These findings suggest a high cumulative incidence of infection and seroconversion, which may have contributed to the observed deceleration of infection rates, but was not sufficient to prevent the second epidemic wave that struck Madagascar in Spring 2021. FUNDING: This project was funded by the United States Agency for International Development.
Asunto(s)
Anticuerpos Antivirales/sangre , Donantes de Sangre , COVID-19/epidemiología , Epidemias , SARS-CoV-2/inmunología , COVID-19/inmunología , Femenino , Humanos , Incidencia , Madagascar/epidemiología , Masculino , Vigilancia de la Población , Seroconversión , Estudios SeroepidemiológicosRESUMEN
BACKGROUND: Following the first detection of SARS-CoV-2 in passengers arriving from Europe on 19 March 2020, Madagascar took several mitigation measures to limit the spread of the virus in the country. METHODS: Nasopharyngeal and/or oropharyngeal swabs were collected from travellers to Madagascar, suspected SARS-CoV-2 cases and contact of confirmed cases. Swabs were tested at the national reference laboratory using real-time RT-PCR. Data collected from patients were entered in an electronic database for subsequent statistical analysis. All distribution of laboratory-confirmed cases were mapped, and six genomes of viruses were fully sequenced. RESULTS: Overall, 26,415 individuals were tested for SARS-CoV-2 between 18 March and 18 September 2020, of whom 21.0% (5,553/26,145) returned positive. Among laboratory-confirmed SARS-CoV-2-positive patients, the median age was 39 years (IQR: 28-52), and 56.6% (3,311/5,553) were asymptomatic at the time of sampling. The probability of testing positive increased with age with the highest adjusted odds ratio of 2.2 [95% CI: 1.9-2.5] for individuals aged 49 years and more. Viral strains sequenced belong to clades 19A, 20A and 20B indicative of several independent introduction of viruses. CONCLUSIONS: Our study describes the first wave of the COVID-19 in Madagascar. Despite early strategies in place Madagascar could not avoid the introduction and spread of the virus. More studies are needed to estimate the true burden of disease and make public health recommendations for a better preparation to another wave.
Asunto(s)
COVID-19/epidemiología , Adulto , Infecciones Asintomáticas/epidemiología , COVID-19/diagnóstico , COVID-19/transmisión , Prueba de Ácido Nucleico para COVID-19 , Monitoreo Epidemiológico , Femenino , Genoma Viral/genética , Humanos , Madagascar/epidemiología , Masculino , Persona de Mediana Edad , Nasofaringe/virología , SARS-CoV-2/clasificación , SARS-CoV-2/genética , SARS-CoV-2/aislamiento & purificación , ViajeRESUMEN
INTRODUCTION: sickle cell trait is the heterozygous form of sickle-cell disease. Patients with sickle cell trait can synthesize normal hemoglobin A and hemoglobin S. This condition has no recognizable clinical signs; then subjects with sickle cell trait, ignoring their genetic status, can be found among blood donors. This can have severe impact on donors´ health status and on that of recipients, especially if these have sickle-cell trait. The purpose of our study is to determine the prevalence of sickle cell trait in blood donors. METHODS: we conducted a 4-month descriptive prospective study (January-May 2017) at the Haute Matsiatra Regional Blood Transfusion Center (RBTC). All donors were screened by Emmel test and positive cases were confirmed by hemoglobin electrophoresis. RESULTS: the study involved 427 donors, of whom 332 were men and 95 women (sex ratio 3.4). The average age of blood donors was 32.72, ranging from 18 to 64 years. Emmel test was positive in 5 donors (1.17%). These patients had the AS genotype confirmed by hemoglobin electrophoresis. CONCLUSION: the results of this study reveal the presence of sickle cell trait among blood donors at the CRTS. Most of them ignore their sickle cell status before blood donation. Quality and safety of blood and blood products are mandatory, hence the importance of screening among blood donors is a current relevant issue.
Asunto(s)
Donantes de Sangre/estadística & datos numéricos , Rasgo Drepanocítico/sangre , Rasgo Drepanocítico/epidemiología , Adolescente , Adulto , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/epidemiología , Bancos de Sangre/organización & administración , Bancos de Sangre/estadística & datos numéricos , Transfusión Sanguínea , Femenino , Humanos , Madagascar/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Programas Médicos Regionales/organización & administración , Programas Médicos Regionales/estadística & datos numéricos , Adulto JovenRESUMEN
INTRODUCTION: The diagnosis of post streptococcal diseases is usually confirmed by immunological tests. Only the antistreptolysin O is usually prescribed by physician. This study aimed to describe the current practice of these requests in Antananarivo. METHODS: It was a retrospective and descriptive study conducted at the Para clinic Unit of Immunology at the University Center Hospital of Antananarivo. We analyzed all requests during seven years, from January 2003 to December 2009. We looked at age, gender, and clinical symptoms which led to the request and the result for each request. RESULTS: We retained 4143 requests for antistreptolysin O titration in our study. The mean age of the study participants was 32.9 years with 18.3% of participants being less than 15 years old. The main symptoms leading to the request of this analysis were rheumatologic (41%), followed by neurological (13.9%) and cardiologic symptoms (8.5%) and 19.4% were prescribed for various symptoms. Only 15% of all requests had a value more than 200 U/ml. CONCLUSION: Our study found that in most of requests, ASO titre levels were not significant.
Asunto(s)
Estreptolisinas/sangre , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Proteínas Bacterianas/sangre , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Madagascar , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Pruebas Serológicas , Distribución por Sexo , Adulto JovenRESUMEN
OBJECTIVE: To assess the usefulness of enzyme-linked immunosorbent assay (ELISA) assessment of the combination of bullous pemphigoid antigen 1 (BPAG1) and BPAG2 in the diagnosis of bullous pemphigoid (BP). DESIGN: Retrospective study of serum samples from patients with BP. SETTING: Tertiary care center. PATIENTS: A total of 190 patients with newly diagnosed BP and 78 controls with other autoimmune bullous diseases. INTERVENTION: Serum samples were tested using commercialized BPAG1 and BPAG2 ELISA and indirect immunofluorescence (IIF). MAIN OUTCOME MEASURES: The sensitivity and specificity of ELISA for the combination of BPAG1 and BPAG2 in the diagnosis of BP were contrasted with ELISA for each of the antigens alone and with IIF. RESULTS: The sensitivity and specificity of ELISA for the combination of BPAG1 and BPAG2 were 87% and 88%, respectively, compared with 79% and 90% for BPAG2 ELISA, 61% and 96% for BPAG1 ELISA, and 81% and 63% for IIF. The combination of BPAG1 ELISA and BPAG2 ELISA permitted 8% and 16% gains in sensitivity compared with each of BPAG2 ELISA and BPAG1 ELISA alone, respectively. Anti-BPAG1 antibodies were detected in 15 of 40 BP serum samples with no anti-BPAG2 antibodies (38%) and in 8 of 13 serum samples from patients with BP and mucosal involvement (62%) compared with 2 of 22 samples of cicatricial pemphigoid (P = .002) and 0 of 16 epidermolysis bullosa acquisita serum samples (P < .001). The BPAG2 ELISA values were more closely correlated with initial extent of BP lesions (r = 0.44, P < .001) than BPAG1 ELISA values (r = 0.16, P = .03). CONCLUSION: Since the combination of BPAG1 and BPAG2 ELISA only slightly increases the sensitivity of BP diagnosis over BPAG2 ELISA alone, BPAG1 ELISA could be adequately proposed in a minority of BP cases with mucosal involvement and in those with no circulating anti-BPAG2 antibodies.